Head and neck cancer radiotherapy amid COVID-19 pandemic: Report from Milan, Italy.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 16 05 2020
accepted: 20 05 2020
pubmed: 20 6 2020
medline: 21 7 2020
entrez: 20 6 2020
Statut: ppublish

Résumé

Management of head and neck cancers (HNC) in radiation oncology in the coronavirus disease 2019 (COVID-19) era is challenging. Aim of our work is to report organization strategies at a radiation therapy (RT) department in the first European area experiencing the COVID-19 pandemic. We focused on (a) dedicated procedures for HNC, (b) RT scheduling, and (c) health care professionals' protection applied during the COVID-19 breakdown (from March 1, 2020 to April 30, 2020). Applied procedures are reported and discussed. Forty-three patients were treated. Image-guided, intensity modulated RT was performed in all cases. Median overall treatment time was 50 (interquartile range: 47-54.25) days. RT was interrupted/delayed in seven patients (16%) for suspected COVID-19 infection. Two health professionals managing HNC patients were proven as COVID-19 positive. Adequate and well-timed organization allowed for the optimization of HNC patients balancing at the best of our possibilities patients' care and personnel's safety.

Sections du résumé

BACKGROUND BACKGROUND
Management of head and neck cancers (HNC) in radiation oncology in the coronavirus disease 2019 (COVID-19) era is challenging. Aim of our work is to report organization strategies at a radiation therapy (RT) department in the first European area experiencing the COVID-19 pandemic.
METHODS METHODS
We focused on (a) dedicated procedures for HNC, (b) RT scheduling, and (c) health care professionals' protection applied during the COVID-19 breakdown (from March 1, 2020 to April 30, 2020).
RESULTS RESULTS
Applied procedures are reported and discussed. Forty-three patients were treated. Image-guided, intensity modulated RT was performed in all cases. Median overall treatment time was 50 (interquartile range: 47-54.25) days. RT was interrupted/delayed in seven patients (16%) for suspected COVID-19 infection. Two health professionals managing HNC patients were proven as COVID-19 positive.
CONCLUSION CONCLUSIONS
Adequate and well-timed organization allowed for the optimization of HNC patients balancing at the best of our possibilities patients' care and personnel's safety.

Identifiants

pubmed: 32557972
doi: 10.1002/hed.26319
pmc: PMC7323327
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1482-1490

Informations de copyright

© 2020 Wiley Periodicals, Inc.

Références

Head Neck. 2020 Jun;42(6):1173-1178
pubmed: 32329953
Radiother Oncol. 2012 Sep;104(3):343-8
pubmed: 22853852
Clin Oncol (R Coll Radiol). 2020 Jul;32(7):e160-e161
pubmed: 32354669
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Head Neck. 2020 Jun;42(6):1214-1217
pubmed: 32329948
JAMA Otolaryngol Head Neck Surg. 2020 May 1;146(5):455-464
pubmed: 32239201
Strahlenther Onkol. 2016 Jun;192(6):377-85
pubmed: 26972085
J Otolaryngol Head Neck Surg. 2015 May 13;44:17
pubmed: 25964113
Radiother Oncol. 2020 Oct;151:314-321
pubmed: 32730830
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Graefes Arch Clin Exp Ophthalmol. 2020 May;258(5):1049-1055
pubmed: 32124000
Head Neck. 2020 Jul;42(7):1367-1373
pubmed: 32358855
Lancet. 2020 Mar 7;395(10226):760-762
pubmed: 32151334
Phys Med. 2015 Dec;31(8):1015-1021
pubmed: 26459318
Otolaryngol Head Neck Surg. 2020 Jun;162(6):804-808
pubmed: 32286909
Clin Infect Dis. 2020 Nov 19;71(16):2218-2221
pubmed: 32179890
Front Oncol. 2020 Mar 24;10:398
pubmed: 32266158
Head Neck. 2020 Jun;42(6):1259-1267
pubmed: 32270581
Oral Oncol. 2020 Mar;102:104561
pubmed: 31918175
JAMA Otolaryngol Head Neck Surg. 2019 Feb 1;145(2):166-177
pubmed: 30383146
Head Neck. 2020 Jun;42(6):1147-1149
pubmed: 32343444
Head Neck. 2020 Jun;42(6):1150-1152
pubmed: 32338797
Acta Oncol. 2013 Feb;52(2):270-6
pubmed: 23173758
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Eur Ann Otorhinolaryngol Head Neck Dis. 2020 May;137(3):159-160
pubmed: 32303485
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):600-601
pubmed: 32199942
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Head Neck. 2020 Jul;42(7):1482-1490
pubmed: 32557972
J Otolaryngol Head Neck Surg. 2017 Apr 4;46(1):29
pubmed: 28376866

Auteurs

Daniela Alterio (D)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Stefania Volpe (S)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Giulia Marvaso (G)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Irene Turturici (I)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Annamaria Ferrari (A)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Maria Cristina Leonardi (MC)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Roberta Lazzari (R)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Massimo Sarra Fiore (MS)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Giammaria Bufi (G)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Federica Cattani (F)

Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Camilla Arrobbio (C)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Filippo Patti (F)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Alessia Casbarra (A)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Iacopo Cavallo (I)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Fabrizio Mastrilli (F)

Medical Administration, CMO, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Roberto Orecchia (R)

Scientific Direction, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Barbara Alicja Jereczek-Fossa (BA)

Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH